Grant GrossMendelsohn LLC Has $567,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Grant GrossMendelsohn LLC cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 2.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,658 shares of the medical research company’s stock after selling 200 shares during the quarter. Grant GrossMendelsohn LLC’s holdings in Edwards Lifesciences were worth $567,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in EW. Avanza Fonder AB acquired a new stake in Edwards Lifesciences in the 4th quarter worth approximately $4,845,000. RDA Financial Network lifted its stake in shares of Edwards Lifesciences by 1.6% in the fourth quarter. RDA Financial Network now owns 33,770 shares of the medical research company’s stock worth $2,500,000 after buying an additional 523 shares during the last quarter. Empirical Asset Management LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $257,000. Central Valley Advisors LLC raised its holdings in Edwards Lifesciences by 13.8% in the 4th quarter. Central Valley Advisors LLC now owns 17,639 shares of the medical research company’s stock worth $1,306,000 after acquiring an additional 2,145 shares during the period. Finally, Gateway Investment Advisers LLC raised its holdings in Edwards Lifesciences by 97.8% in the 4th quarter. Gateway Investment Advisers LLC now owns 11,581 shares of the medical research company’s stock worth $857,000 after acquiring an additional 5,726 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 0.1 %

Shares of NYSE:EW opened at $69.77 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market cap of $41.15 billion, a P/E ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company’s 50-day moving average price is $71.99 and its two-hundred day moving average price is $71.60.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the business posted $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock worth $2,195,180 over the last 90 days. Insiders own 1.27% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EW. Morgan Stanley reaffirmed an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Royal Bank of Canada lifted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Citigroup raised their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $78.48.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.